{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T02:33:04Z","timestamp":1784860384995,"version":"3.55.0"},"reference-count":78,"publisher":"Informa UK Limited","issue":"3","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Emerging Drugs"],"published-print":{"date-parts":[[2025,7,3]]},"DOI":"10.1080\/14728214.2025.2517582","type":"journal-article","created":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T22:04:26Z","timestamp":1749679466000},"page":"179-190","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":3,"title":["Motor fluctuations in Parkinson disease \u2013 a mini-review of emerging drugs"],"prefix":"10.1080","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8250-5915","authenticated-orcid":false,"given":"Priti","family":"Gros","sequence":"first","affiliation":[{"name":"Toronto Western Hospital","place":["Toronto, Canada"]},{"name":"University of Toronto","place":["Toronto, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4011-0736","authenticated-orcid":false,"given":"Laura","family":"Armengou Garcia","sequence":"additional","affiliation":[{"name":"Toronto Western Hospital","place":["Toronto, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7568-1645","authenticated-orcid":false,"given":"Susan H.","family":"Fox","sequence":"additional","affiliation":[{"name":"Toronto Western Hospital","place":["Toronto, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,6,16]]},"reference":[{"key":"e_1_3_4_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-7568(24)00094-1"},{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01419-8"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-020-0117-1"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01429-0"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-020-00889-4"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-023-02679-6"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.27882"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2015.11.007"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.28970"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-200003000-00003"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20279"},{"issue":"12","key":"e_1_3_4_13_1","first-page":"S255","article-title":"Exploring the clinical burden of off periods in Parkinson disease","volume":"26","author":"Tanner CM.","year":"2020","unstructured":"Tanner CM. Exploring the clinical burden of off periods in Parkinson disease. Am J Manag Care. 2020;26(12 Suppl):S255\u2013s264.","journal-title":"Am J Manag Care"},{"issue":"12","key":"e_1_3_4_14_1","first-page":"S265","article-title":"The economic impact of off periods in Parkinson disease","volume":"26","author":"Abeynayake I","year":"2020","unstructured":"Abeynayake I, Tanner CM. The economic impact of off periods in Parkinson disease. Am J Manag Care. 2020;26(12 Suppl):S265\u2013s269.","journal-title":"Am J Manag Care"},{"key":"e_1_3_4_15_1","unstructured":"LLP SI. Global Parkinson\u2019s disease treatment market Size to Worth USD 9.14 billion by 2033 | CAGR of 6.41%. 2024 [cited 2025 May 16]. Available from: https:\/\/www.globenewswire.com\/news-release\/2024\/06\/24\/2903301\/0\/en\/Global-Parkinson-s-Disease-Treatment-Market-Size-To-Worth-USD-9-14-Billion-By-2033-CAGR-Of-6-41.html"},{"key":"e_1_3_4_16_1","unstructured":"Payal Suresh Ghurde NSS. Levodopa market by form (tablets capsules powder liquid) by route of administration (oral parenteral) by distribution channels (Hospital pharmacies retail pharmacies online pharmacies other): global opportunity analysis and industry forecast 2023\u20132032. 2024 [cited 2025 May 16]. Available from: https:\/\/www.alliedmarketresearch.com\/levodopa-market-A213646"},{"key":"e_1_3_4_17_1","unstructured":"Research GV. Parkinson\u2019s disease treatment market Size share & trends analysis report by drug class (carbidopa-levodopa dopamine agonists MAO-B inhibitors) by distribution channel (Hospital pharmacy retail pharmacy) by region and segment forecasts 2025 \u2013 2030. 2025 [cited 2025 May 16]. Available from: https:\/\/www.grandviewresearch.com\/industry-analysis\/parkinsons-disease-treatment-market"},{"key":"e_1_3_4_18_1","unstructured":"Healthcare G. 7MM PD market to grow by $4.5bn between 2023 and 2033. 2025 [cited 2025 May 16]. Available from: https:\/\/www.clinicaltrialsarena.com\/analyst-comment\/7mm-pd-market-grow-2023-2033\/?cf-view"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-200203000-00004"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(24)00116-9"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/nmo.70013"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.15.25"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000027511"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-022-01331-3"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-022-00291-1"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.2009.06036.x"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(22)00400-8"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(24)00052-8"},{"key":"e_1_3_4_29_1","article-title":"THOR 201: a proof-of-concept study assessing safety, tolerability, pharmacokinetics and pharmacodynamics of L-dopa delivered by Impel\u2019s precision olfactory delivery (PODTM) to Parkinson\u2019s disease patients in an off episode (in the presence of dopa decarboxylase inhibitor)","volume":"34","author":"Shrewsbury S","year":"2019","unstructured":"Shrewsbury S, Campbell J, Swardstrom M, et al. THOR 201: a proof-of-concept study assessing safety, tolerability, pharmacokinetics and pharmacodynamics of L-dopa delivered by Impel\u2019s precision olfactory delivery (PODTM) to Parkinson\u2019s disease patients in an off episode (in the presence of dopa decarboxylase inhibitor). Mov Disord. 2019 [Cited 2025 June 11];34(suppl 2). https:\/\/www.mdsabstracts.org\/abstract\/thor-201-a-proof-of-concept-study-assessing-safety-tolerability-pharmacokinetics-and-pharmacodynamics-of-l-dopa-delivered-by-impels-precision-olfactory-delivery-podtm-to-parkinson\/","journal-title":"Mov Disord"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.17925\/USN.2020.16.1.25"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1097\/WNF.0000000000000540"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13796"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(18)30239-4"},{"key":"e_1_3_4_34_1","unstructured":"Canada P. APO-go\u00ae PEN is available in Canada. 2024 [cited 2025 Jan 3]. Available from: https:\/\/www.parkinson.ca\/apo-go-pen-is-available-in-canada\/"},{"key":"e_1_3_4_35_1","unstructured":"Carvalho T. Kynmobi (apomorphine) for Parkinson\u2019s disease. 2023 [cited 2025 Jan 3]. Available from: https:\/\/parkinsonsnewstoday.com\/kynmobi-apomorphine-parkinsons-disease\/#Kynmobi"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-024-12323-2"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/ene.15635"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2021.806618"},{"key":"e_1_3_4_39_1","unstructured":"Meglio M. Cerevel\u2019s tavapadon meets primary end point in phase 3 TEMPO-3 study of Parkinson disease. 2024 [cited 2025 Jan 3]. Available from: https:\/\/www.neurologylive.com\/view\/cerevel-tavapadon-meets-primary-end-point-phase-3-tempo-3-study-parkinsons"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1177\/1756286420911296"},{"key":"e_1_3_4_41_1","unstructured":"Matsupexole: synapse by patsnap. [cited 2025 Jan 28]. Available from: https:\/\/synapse.patsnap.com\/drug\/19a7e26a630e4a53b76c7fe546285d59"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.0c02081"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.120.000438"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102882"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.818355"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.28686"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2011.12.004"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.27259"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1602423"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1124\/pr.111.005678"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-024-00836-6"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2022.105697"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.27462"},{"key":"e_1_3_4_54_1","unstructured":"Bratulic A. Failed studies prompt Lundbeck to terminate foliglurax in Parkinson\u2019s disease Lu AG06466 in tourette syndrome 2020. [cited 2025 Mar 1]. Available from: https:\/\/firstwordpharma.com\/story\/4981057"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2018.10.005"},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-03802-y"},{"key":"e_1_3_4_57_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.29726"},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.14893"},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.119.262865"},{"key":"e_1_3_4_60_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.27783"},{"key":"e_1_3_4_61_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-019-03745-2"},{"key":"e_1_3_4_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2017.05.027"},{"key":"e_1_3_4_63_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.22341"},{"key":"e_1_3_4_64_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-023-00585-y"},{"key":"e_1_3_4_65_1","doi-asserted-by":"publisher","DOI":"10.3390\/s21124188"},{"key":"e_1_3_4_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)71083-7"},{"key":"e_1_3_4_67_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.27372"},{"key":"e_1_3_4_68_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2021.4736"},{"key":"e_1_3_4_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2008.12.007"},{"key":"e_1_3_4_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2014.10.006"},{"key":"e_1_3_4_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/bs.irn.2017.05.021"},{"key":"e_1_3_4_72_1","doi-asserted-by":"publisher","DOI":"10.14802\/jmd.24227"},{"key":"e_1_3_4_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2012.08.004"},{"key":"e_1_3_4_74_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2023-332551"},{"key":"e_1_3_4_75_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.28507"},{"key":"e_1_3_4_76_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awx118"},{"key":"e_1_3_4_77_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2018-318337"},{"key":"e_1_3_4_78_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-020-00894-7"},{"key":"e_1_3_4_79_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.909936"}],"container-title":["Expert Opinion on Emerging Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14728214.2025.2517582","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T10:20:47Z","timestamp":1774952447000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14728214.2025.2517582"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,16]]},"references-count":78,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,7,3]]}},"alternative-id":["10.1080\/14728214.2025.2517582"],"URL":"https:\/\/doi.org\/10.1080\/14728214.2025.2517582","relation":{},"ISSN":["1472-8214","1744-7623"],"issn-type":[{"value":"1472-8214","type":"print"},{"value":"1744-7623","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,16]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemd20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iemd20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-03-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}